SCHEMBL20203601

SCHEMBL20203601

Cc1nc(C(C)C)ccc1N1CCNCC1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.39
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
GPR119 Q8TDV5 1/20 0.34
PIK3CD O00329 4/20 0.33
PIK3CA P42336 4/20 0.33
PIK3CB P42338 4/20 0.33
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 2/20 0.32
F10 P00742 1/20 0.32
PIM1 P11309 2/20 0.31
CDK4 P11802 2/20 0.31
CDK6 Q00534 1/20 0.31
MAP4K1 Q92918 1/20 0.31
CCND1 P24385 1/20 0.30
PRMT5 O14744 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20203588 0.92 SLC6A2 (0.41) SOS1TLR8TLR7GPR119PIK3CD
SCHEMBL20038317 0.83 RECQL (0.37) SOS1TLR8TLR7GPR119SLC6A2
SCHEMBL18291477 0.82 NOS2 (0.37) SOS1TLR8TLR7SLC6A2SLC6A4
SCHEMBL20037529 0.81 SOS1 (0.35) SOS1TLR8TLR7SLC6A2SLC6A4
SCHEMBL21414487 0.80 SLC6A2 (0.38) SOS1PIK3CDSLC6A2SLC6A4SLC6A3
SCHEMBL20249449 0.80 SOS1 (0.34) SOS1TLR8TLR7SLC6A2SLC6A4
SCHEMBL20203439 0.77 ADRB1 (0.45) CDK4CCND1
SCHEMBL27207129 0.74 HTR7 (0.39) SOS1F10
SCHEMBL15341607 0.74 SLC6A2 (0.41) SOS1TLR8TLR7GPR119SLC6A2
SCHEMBL22860622 0.73 SOS1 (0.38) SOS1SLC6A2SLC6A4SLC6A3F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 SOS1 1416/4885TLR8 2089/4885TLR7 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.